Spero Therapeutics Inc expected to post a loss of 87  cents a share - Earnings Preview

Spero Therapeutics

13/05/2022 23:58

* Spero Therapeutics Inc  SPRO.OQ   SPRO.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 16. 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 64.8% decrease in revenue to $2.567 million from $7.3 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Spero Therapeutics
Inc is
for a loss of 87 cents per share. For the same quarter last
year, the company reported a loss of 66 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 1.5%
in the last three months. ​
    * Wall Street's median 12-month price target for Spero
Therapeutics Inc is $37​, above​ its last closing price
of $1.71. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.78       -0.75      -0.90     Missed  -20.4
 Sep. 30 2021  -0.64       -0.66      -0.70     Missed  -5.5
 Jun. 30 2021  -0.74       -0.75      -0.63     Beat    16.1​
 Mar. 31 2021  -0.64       -0.64      -0.66     Missed  -2.3
 ​​Dec.        -0.65       -0.74      -0.68     Beat    8.5
 31 2020                                                
 Sep. 30 2020  -0.84       -0.87      -0.86     Beat    1.3​
 Jun. 30 2020  -1.08       -1.12      -0.85     Beat    24.3
 Mar. 31 2020  -1.23       -1.25      -1.19     Beat    4.8
 This summary was machine generated May 13 at 22:58 GMT.  All
figures in US dollars  unless otherwise stated